PolyPid
Polymer Lipid Encapsulation Technology
Startup Public Health Tech & Life Sciences Est. 2008
🌐 WebsiteLinkedInTwitterCareers
Total Raised
$239.24M
Public
Last Round
$26.7M
14 rounds
Investors
7
7 public
Team
4
51-200 employees
Confidence
91/100
News
131
articles
Patents
1
About
PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with active pharmaceutical ingredients to enable the precise delivery of drugs at optimal release rates over durations ranging from days to months. PolyPid’s lead product candidate, D-PLEX100, is in a phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the company’s OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2CB2B2C
Tags
orthopedicsdentaldrug-deliverypharma-companiessustained-releasetherapeuticspain-reliefcancerbiopharmaceuticalsurgeons
Funding & Events
Sep 2019
E Round $50M
Nov 2018
E Round $15M
Nov 2016
Debt Financing $5.3M
Mar 2023
Exit Undisclosed
Jun 2025
PIPE $26.7M
Jun 2020
Exit Undisclosed
Jan 2024
PIPE $16.2M
Rosalind Advisors, DAFNA Capital Management
Jan 2012
B Round $2M
Jan 2010
A Round $1.4M
Feb 2016
D Round $22M
Shavit Capital Fund (Lead), Chaim Hurvitz, Aurum Ventures M.K.I
Feb 2016
C Round $8.14M
Aurum Ventures M.K.I, Shavit Capital Fund
Dec 2024
PIPE $14.5M
Aug 2024
PIPE $8.1M
Undisclosed Investor(s)
Apr 2022
Debt Financing $12.5M
Kreos Capital
News (131)
Oct 29, 2025 · finance.yahoo.com
growth-positive
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
Product StageFDA approved/pending approval
Sep 30, 2025 · finance.yahoo.com
growth-positive
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
Product StageFDA approved/pending approval
Sep 17, 2025 · finance.yahoo.com
growth-positive
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
Product StageManagement Changes
Sep 16, 2025 · finance.yahoo.com
growth-positive
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
Product Stage
Sep 3, 2025 · finance.yahoo.com
growth-positive
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Product StageInvestment
Sep 2, 2025 · finance.yahoo.com
growth-positive
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
Product StageFDA approved/pending approval
Aug 14, 2025 · finance.yahoo.com
growth-positive
PolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
Product StageInvestment
Aug 13, 2025 · finance.yahoo.com
growth-positive
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Product StageManagement ChangesPartners
Aug 12, 2025 · finance.yahoo.com
growth-positive
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
Management ChangesProduct Stage
Jul 30, 2025 · finance.yahoo.com
growth-positive
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
Product Stage
Jul 16, 2025 · finance.yahoo.com
growth-positive
PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits
Product Stage
Jul 15, 2025 · finance.yahoo.com
growth-positive
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
Product Stage
Jul 15, 2025 · finance.yahoo.com
growth-positive
Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech
Product StageAcquisition
Jun 22, 2025 · finance.yahoo.com
growth-positive
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
Product StageInvestment
Jun 16, 2025 · finance.yahoo.com
growth-positive
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
Investment
Jun 10, 2025 · en.globes.co.il
growth-positive
The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery.
Product StagePartnersInvestment
Jun 9, 2025 · finance.yahoo.com
growth-positive
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
Product Stage
Jun 9, 2025 · finance.yahoo.com
growth-positive
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
Product Stage
Jun 6, 2025 · finance.yahoo.com
growth-positive
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
Product Stage
Jun 6, 2025 · finance.yahoo.com
growth-positive
Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
Investment
+ 111 more articles
Details
Product Stage
Clinical Trial
Employees
51-200
Exact Count
68
District
Center District
Founded
2008
Registrar
514105923
Crunchbase
polypid
Locations
HaSivim Street 18, Petah Tikva, Israel
Links
Website
www.polypid.com
LinkedIn
Profile
Twitter
Profile
Careers
Open positions
Admin
Last Update
Oct 29, 2025
Verified by
Yanina Wainscheinker
Claimed
Yes
Missing
markets, not claimed
Team (4)
Dikla Czaczkes Akselbrad
CEO
Jonny Missulawin
CFO
Ori Warshavsky
Chief Operating Officer - US
Dalit Hazan
Executive Vice President R&D, Clinical and Regulatory Affairs
Internal
Created by
Rebecca Mack (rebeccamack26@gmail.com)
Created
2014-07-28T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)
Status
Public on NASDAQ on Jun, 2020;
Finder · PolyPid · 2026